Efficacy and Safety of rhGH (Jintropin ) in Pediatric Participants With ISS

  • participants needed
  • sponsor
    GeneScience Pharmaceuticals Co., Ltd.
Updated on 9 December 2021
growth hormone
hormone therapy
stimulation test
growth hormone treatment


Phase 1: To evaluate the safety and efficacy of 0.05mg/kg/d of rhGH (Jintropin) in the treatment of children with idiopathic short stature (ISS) in 52 weeks.

Phase 2: To evaluate the safety and efficacy of rhGH (Jintropin) in the treatment of children with ISS in 2 years

Condition Dwarfism, Idiopathic Short Stature, Severe Short Stature, short stature
Treatment Negative Control
Clinical Study IdentifierNCT03635580
SponsorGeneScience Pharmaceuticals Co., Ltd.
Last Modified on9 December 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note